Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NYSE | Common Stock
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.
In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma.
It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 24 | 0.00 Increased by +100.00% | -1.40 Increased by +100.00% |
| Feb 29, 24 | -1.81 Increased by +45.48% | -1.41 Decreased by -28.37% |
| Nov 14, 23 | -1.50 Increased by +14.29% | -1.34 Decreased by -11.94% |
| Jul 31, 23 | -1.32 Increased by +78.74% | -1.21 Decreased by -9.09% |
| May 12, 23 | -1.03 Increased by +65.32% | -1.41 Increased by +26.95% |
| Mar 23, 23 | -3.32 Decreased by -10.30% | -1.22 Decreased by -172.13% |
| Nov 9, 22 | -1.75 Increased by +33.46% | -2.34 Increased by +25.21% |
| Aug 5, 22 | -6.21 Decreased by -92.26% | -2.58 Decreased by -140.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Increased by +100.00% | -144.76 M Increased by +28.02% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -102.57 M Decreased by -48.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -90.35 M Increased by +55.56% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -70.49 M Increased by +27.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | -215.08 M Decreased by -213.19% | -201.11 M Decreased by -287.59% | Increased by +93.50% Increased by +442.42% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -68.85 M Decreased by -26.65% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 215.08 M Increased by +131.43% | -203.29 M Increased by +3.48% | Decreased by -94.52% Increased by +58.30% |
| Mar 31, 22 | 318.85 M Increased by +627.59% | -97.03 M Increased by +63.38% | Decreased by -30.43% Increased by +94.97% |